|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When SB2-flot-2 cells were compared with SB2-vector-control cells on a cancer gene pathway array, SB2-flot-2 cells had increased expression of protease activated receptor 1 (PAR-1) mRNA, a transmembrane, G-protein-coupled receptor involved in melanoma progression.
|
15492257 |
2004 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Flot-2 binds to PAR-1, a known upstream mediator of major signal transduction pathways implicated in cell growth and metastasis, and may thereby influence tumor progression.
|
15492257 |
2004 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
When SB2-flot-2 cells were compared with SB2-vector-control cells on a cancer gene pathway array, SB2-flot-2 cells had increased expression of protease activated receptor 1 (PAR-1) mRNA, a transmembrane, G-protein-coupled receptor involved in melanoma progression.
|
15492257 |
2004 |
|
Tumor Progression
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Flot-2 binds to PAR-1, a known upstream mediator of major signal transduction pathways implicated in cell growth and metastasis, and may thereby influence tumor progression.
|
15492257 |
2004 |
|
melanoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, flot-2 overexpression is associated with melanoma progression, with increased PAR-1 expression, and with transformation of SB2 melanoma cells to a highly metastatic line.
|
15492257 |
2004 |
|
melanoma
|
0.030 |
AlteredExpression
|
disease |
LHGDN |
In conclusion, flot-2 overexpression is associated with melanoma progression, with increased PAR-1 expression, and with transformation of SB2 melanoma cells to a highly metastatic line.
|
15492257 |
2004 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma.
|
17013097 |
2006 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
LHGDN |
High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma.
|
17013097 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The subpopulation of human colorectal tumor cells with an ESA(+)CD44(+) phenotype are uniquely responsible for tumorigenesis and have the capacity to generate heterogeneous tumors in a xenograft setting (i.e.CoCSC).
|
18560594 |
2008 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The subpopulation of human colorectal tumor cells with an ESA(+)CD44(+) phenotype are uniquely responsible for tumorigenesis and have the capacity to generate heterogeneous tumors in a xenograft setting (i.e.CoCSC).
|
18560594 |
2008 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using QRT-PCR data we identified a four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17) that predicts M/NM status with 77% success in a separate 79-sample validation group of HNSCC samples.
|
18679425 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ESA+CD44+CD24-/low cells had up to 100- to 1000-fold greater tumor-initiating capability than the MCF-7 cells.
|
21192833 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Resveratrol has been shown to have strong hypolipidemic effect on normal adipocytes and as hyper-lipogenesis is a hallmark of cancer cell physiology, the effect of resveratrol on lipid synthesis in cancer stem-like cells (CD24(-)/CD44(+)/ESA(+)) that were isolated from both ER+ and ER- breast cancer cell lines was examined.
|
21188630 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human pancreatic CSCs (CD133(+)CD44(+)CD24(+)ESA(+)) are highly tumorigenic and form subcutaneous tumors in NOD/SCID mice.
|
21304978 |
2011 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Resveratrol has been shown to have strong hypolipidemic effect on normal adipocytes and as hyper-lipogenesis is a hallmark of cancer cell physiology, the effect of resveratrol on lipid synthesis in cancer stem-like cells (CD24(-)/CD44(+)/ESA(+)) that were isolated from both ER+ and ER- breast cancer cell lines was examined.
|
21188630 |
2011 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Inhibition of the HR pathway effectively sterilised the CD24(- ) ESA(+) sorted MDA-MB231 cells but had no effect on the unsorted cells or MDA468 control breast cancer cell line.
|
21558789 |
2011 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Inhibition of the HR pathway effectively sterilised the CD24(- ) ESA(+) sorted MDA-MB231 cells but had no effect on the unsorted cells or MDA468 control breast cancer cell line.
|
21558789 |
2011 |
|
Adenocarcinoma of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression patterns of the pancreatic cancer stem cell surface markers CD44, CD24 and ESA were diverse in different pancreatic adenocarcinoma cell lines and changed with their local microenvironment.
|
21813394 |
2011 |
|
Hyperactive behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Resveratrol has been shown to have strong hypolipidemic effect on normal adipocytes and as hyper-lipogenesis is a hallmark of cancer cell physiology, the effect of resveratrol on lipid synthesis in cancer stem-like cells (CD24(-)/CD44(+)/ESA(+)) that were isolated from both ER+ and ER- breast cancer cell lines was examined.
|
21188630 |
2011 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Resveratrol has been shown to have strong hypolipidemic effect on normal adipocytes and as hyper-lipogenesis is a hallmark of cancer cell physiology, the effect of resveratrol on lipid synthesis in cancer stem-like cells (CD24(-)/CD44(+)/ESA(+)) that were isolated from both ER+ and ER- breast cancer cell lines was examined.
|
21188630 |
2011 |
|
estrogen receptor-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Resveratrol has been shown to have strong hypolipidemic effect on normal adipocytes and as hyper-lipogenesis is a hallmark of cancer cell physiology, the effect of resveratrol on lipid synthesis in cancer stem-like cells (CD24(-)/CD44(+)/ESA(+)) that were isolated from both ER+ and ER- breast cancer cell lines was examined.
|
21188630 |
2011 |
|
Tumor Cell Invasion
|
0.090 |
GeneticVariation
|
phenotype |
BEFREE |
An in-frame deletion mutant of the ESA_01081 homolog and its cognate complementation strain were constructed and characterized for pathogenesis (adhesion/invasion potentials to human intestinal cells and in vivo rat pup challenge assay), biofilm formation, resistance to oxidative stress and induction of IL-8 secretion.
|
22770741 |
2012 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Here, we report that upregulation of hyaluronan synthase 2 (HAS2) occurs in highly metastatic breast cancer stem-like cells (CSC) defined by CD44(+)/CD24(-)/ESA(+) phenotype, where it plays a critical role in the generation of a prometastatic microenvironment in breast cancer.
|
22113945 |
2012 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Here, we report that upregulation of hyaluronan synthase 2 (HAS2) occurs in highly metastatic breast cancer stem-like cells (CSC) defined by CD44(+)/CD24(-)/ESA(+) phenotype, where it plays a critical role in the generation of a prometastatic microenvironment in breast cancer.
|
22113945 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population.
|
23208501 |
2013 |